Publications
Lee G, Haugg F, Bontempi D, He J, Bitterman DS, Pai S, Guthier C, Fitzgerald KJ, Kozono DE, Kann BH, Aerts HJWL, Mak RH. Multimodal Assessment of Biological Age Following Radiation Therapy Among Patients With Early-Stage NSCLC. JAMA network open. 2026. PMID: 41949867
Nikkilä J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, Monni V, Harris RS, Pettitt SJ, Ashworth A, Lord CJ. Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. British journal of cancer. 2026. PMID: 41699262
Fann JR, Vanderlan J, Brewer BW, Corbett C, Keller J, Lahijani S, Niazi SK, Riba MB, Andersen B, Atreya CE, Braun I, Breitbart WS, Channa Y, Farabelli J, Fleishman S, Garcia S, Greenberg DB, Handzo RGF, Horyna A, Huang CH, Hutchinson S, Johns S, La Cava S, Leeper H, Martin S, Mukherjee D, Pailler M, Parnes F, Rao V, Rocha-Cadman X, Scher E, Schuster J, Thompson LMA, Usher A, Valentine AD, Montgomery S, Darlow S. NCCN Guidelines® Insights: Distress Management, Version 1.2026. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41956112
Walling AM, Sak R, Skootsky S, Wenger N, Balabanova N, Friedberg N, Villalona-Calero M, Schwartz G, Singha S, Bray-Hanin L, Anand S, Jagels B, Dahm L, Cabrera M, Bresnahan A, Meyers B, Sonderlund M, Nelson E, Senthil M, Kane S, Hamdan A, Vu P, Venook A, Burgess D, Gold K. BIO26-035: Validation of an Electronic Health Record Phenotype for Advanced Solid Cancer Across Five University of California Health Systems. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41991066
Schwartzberg L, Crawford J, Baird J, Crist K, Marino V, Shah N, Franklin H. CLO26-092: Real-World Use of Eflapegrastim in 14-Day Chemotherapy Cycles/Dose-Dense Regimens. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 42061425
Schwartzberg L, Crawford J, Baird J, Crist K, Marino V, Shah N, Franklin H. CLO26-092: Real-World Use of Eflapegrastim in 14-Day Chemotherapy Cycles/Dose-Dense Regimens. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41911759
Rauschecker A, Romano M, Wei J, Girma S, Beheshtian E, Nedelec P, Eghbali R, Sugrue L, Rubenstein JL. YIA26-002: Automated Segmentation and Radiogenomic Analysis of Primary CNS Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41916413
Rauschecker A, Romano M, Wei J, Girma S, Beheshtian E, Nedelec P, Eghbali R, Sugrue L, Rubenstein JL. YIA26-002: Automated Segmentation and Radiogenomic Analysis of Primary CNS Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41991092
Bowers JT, Vijayanarayanan A, Gill N, Traglia M, Thomas R, Andreadis CB, Ai WZ, Ho C, Kaplan LD, Merrill MH, Seshadri MR, Randall MP, Rubenstein JL, Ganapathi K, Prakash S, Devine WP, Spinner MA. CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS). Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41921576
Bowers JT, Vijayanarayanan A, Gill N, Traglia M, Thomas R, Andreadis CB, Ai WZ, Ho C, Kaplan LD, Merrill MH, Seshadri MR, Randall MP, Rubenstein JL, Ganapathi K, Prakash S, Devine WP, Spinner MA. CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS). Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41991041
Walling AM, Sak R, Skootsky S, Wenger N, Balabanova N, Friedberg N, Villalona-Calero M, Schwartz G, Singha S, Bray-Hanin L, Anand S, Jagels B, Dahm L, Cabrera M, Bresnahan A, Meyers B, Sonderlund M, Nelson E, Senthil M, Kane S, Hamdan A, Vu P, Venook A, Burgess D, Gold K. BIO26-035: MTAP Deficiency in Thoracic Oncology: Bridging Genomic Loss, Survival Deficits, and Immunosuppressive Microenvironments. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41911852
Pan D, Mouhieddine TH, Sheng T, Fu W, Moshier E, Richter J, Parekh S, Jagannath S, Chari A, Rossi AC, Sanchez LJ, Thibaud S, Rodriguez C, Cho HJ, Richard S. Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma. Bone marrow transplantation. 2026. PMID: 41912833
Moss W, Torres R, Sablan JP, Tenorio L, West J, Sabino A, Kwon D, Brett P, Paulino Y, Warnakulasuriya S. Areca nut policy developments in the Asia-Pacific: Warning labels. Journal of Cancer Policy. 2026. PMID: 41921913
Rugo HS, Pluard TJ, Sharma P, Melisko M, Al-Jazayrly G, Ji Y, Vidula N, Ellerton J, Smakal M, Zimovjanova M, Weng D. OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer. Breast cancer research and treatment. 2026. PMID: 41910867
Rugo HS, Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Lynce F, Cottu P, Thill M, Curigliano G. Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice. Breast (Edinburgh, Scotland). 2026. PMID: 41950642
Song H, Xu J, Velazquez-Arcelay K, Demirci A, Raizenne BL, Hsu SC, Choi J, Pham JH, Chen YA, Weinstein HNW, Salzman I, Tsui M, Akutagawa J, Adingo W, Goldschmidt E, Carroll PR, Hong JC, Heaphy CM, Cooperberg MR, Greenland N, Campbell JD, Huang FW. A single-cell and spatial atlas of prostate cancer reveals the combinatorial nature of gene modules underlying lineage plasticity and metastasis. bioRxiv : the preprint server for biology. 2026. PMID: 41928983
Poissonnier A, Rugo HS, Horton W, Kim T, DeLuca A, Egeland EV, Cotechini T, Sivagnanam S, Mori M, Yu Y, Park B, Beelen N, Murugan D, Kirchberger N, Kummar S, Mayer IA, Blackwell K, Hwang ES, Coussens LM. CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41894563
Fu S, Li G, Ming K, Wang J, Guan H, Ai W, Cheng S, Xu Y, Huang L, Xu Z, Fang G, Ke W. Internal Ultrathin Hydrophobic Self-Assembled Capping Layers Enables Moisture-Resistant All-Perovskite Tandems. Advanced materials (Deerfield Beach, Fla.). 2026. PMID: 41885114
Gounder M, Schöffski P, Jones RL, Stacchiotti S, Demetri GD, Cote GM, Agulnik M, Chugh R, Jahan T, Gupta AA, Chen TW, Ratan R, Dileo P, Drilon A, Malouf GG, Szanto A, Gupta N, Tannir NM. Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study. Nature communications. 2026. PMID: 41882006
Wagner AD, Raeisi M, Rakez M, Diasio RD, Margalit O, Zalcberg JR, Venook AP, Douillard JY, Lenz HJ, Heinemann V, Goldberg RM, van Cutsem E, Schmoll HJ, Shi Q, André T, de Gramont A. Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database. European journal of cancer (Oxford, England : 1990). 2026. PMID: 41903302